David W. Denning

Physician with expertise in fungal infections, particularly aspergillosis, antifungal resistance, the treatment of fungal infection and infection in the immunocompromised patient
Graduate of Guys Hospital London in 1980, with training in medicine, paediatrics, gastroenteroloy, haematology, infectious diseases and clinical microbiology, including a 3 year fellowship at Stanford University with Professor David Stevens (1987-1990)
Author of >700 research papers and chapters, mostly on fungal disease, resistance in fungi and treatment of fungal infection.
Co-author of ‘Medicine' with Professor Paul O'Neil and Dr Tim Dornan, an undergraduate textbook of medicine now in its third edition (2008).
Google H-index of 123
Personal citation index of >75,000
Highly cited author globally 2018, 2019, 2020
Research grant income to Manchester University >£30M since 1990
Ex-Director of National Aspergillosis Centre (2009-2020)
Co-ordinator of the International Genome Sequencing project for Aspergillus fumigatus (funded by NIH, Wellcome Trust and Spanish government) 1997-2005
Founder and Editor of Aspergillus website (1998-)
Consultant (current or past) to multiple pharmaceutical companies with regard to antifungal drug discovery including Merck, Pfizer, Schering Plough, Pulmocide, Pulmatrix and Astellas.
Founder of F2G Ltd, an antifungal drug discovery company spun out from Manchester University (1998-).
Founder and Chief Medical Officer of Myconostica (acquired by Trinity Biotech), developing and commercialising molecular diagnostics for fungal disease (2006-2011).
Listed in Who's Who in the World since 1996/7 Listed in Who's Who in Healthcare since 1997 Listed in Who's Who in Science and Technology since 2005, in Who's Who 2013-
Chairman of several international conferences (Trends in Invasive Fungal Infection (x3 1993, 1997 and 1999; Advances against Aspergillosis and Mucormycosis 2004, 2006, 2008, 2010 and 2012, 2014, 2016, 2018, 2020, 2022: Aspergillus Genetics and Genomes Focus Meeting 2004, and other smaller meetings) and sessions at major congresses.
MacFarlane Burnett Lecturer to the Australasian Society of Infectious Diseases, 2005.

Edouard Drouhet medal lecture at the European Confederation of Medical Mycology, 2017
Keynote plenary speaker at the European Conference on Clinical Microbiology and Infectious Diseases, 2008; International Society for Human and Animal Mycology, Tokyo, 2009; Asian Mycological Congress, Beijing, 2013; Trends in Medical Mycology, Copenhagen, 2013, International Union of Microbiological Societies, Montreal, 2014; European Academy of Allergy & Clinical Immunology (EAACI), Lisbon, 2019.

Director of the Leading International Fungal Education (LIFE) program on behalf of the Fungal Infection Trust, 2012 –

Founding President, now Chief Executive of Global Action Fund for Fungal Infections (GAFFI) in Geneva and UK, 2013-, focussed on advocacy for fungal disease to governments and global agencies, including the WHO.

Member of the SEARO Task Force on Antimicrobial Resistance (AMR) (2019 -